You just read:

Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of Once-Daily LATUDA™ (lurasidone HCl) for the Treatment of Patients with Schizophrenia

News provided by

Sunovion Pharmaceuticals Canada Inc.

Jun 15, 2012, 10:00 ET